Cargando…
The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis
Chronic inflammatory bowel disease (IBD) is a condition with multifactorial pathophysiology. To date, there is no permanent cure and the disease is primarily managed by immunosuppressive drugs; long-term use promotes serious side effects including increased risk malignancies. The current study aimed...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522858/ https://www.ncbi.nlm.nih.gov/pubmed/33041796 http://dx.doi.org/10.3389/fphar.2020.556020 |
_version_ | 1783588272704847872 |
---|---|
author | Ahmad, Gulfam Chami, Belal Liu, Yuyang Schroder, Angie L. San Gabriel, Patrick T. Gao, Antony Fong, Genevieve Wang, XiaoSuo Witting, Paul K. |
author_facet | Ahmad, Gulfam Chami, Belal Liu, Yuyang Schroder, Angie L. San Gabriel, Patrick T. Gao, Antony Fong, Genevieve Wang, XiaoSuo Witting, Paul K. |
author_sort | Ahmad, Gulfam |
collection | PubMed |
description | Chronic inflammatory bowel disease (IBD) is a condition with multifactorial pathophysiology. To date, there is no permanent cure and the disease is primarily managed by immunosuppressive drugs; long-term use promotes serious side effects including increased risk malignancies. The current study aimed to target neutrophil-myeloperoxidase, a key contributor to the pathogenesis of IBD, through the use of AZD3241that inhibits extracellular myeloperoxidase. Experimental colitis was induced in C57BL/6 male mice by 2% dextran sodium sulfate in drinking water ad libitum over 9 days. Mice received either normal drinking water and peanut butter (control), 2% DSS in drinking water and peanut butter or 2% DSS in drinking water and AZD3241 (30 mg/kg) dispersed in peanut butter daily for 9 days. Administered AZD3241 attenuated body weight loss (10% p<0.05) and improved clinical score (9 fold p<0.05; a score comprising the time-dependent assessment of stool consistency and extent of rectal bleeding), loss of colonic crypts (p<0.001), preserved surface epithelium (p<0.001) and enhanced expression of the transcription factor Nrf-2 (regulator of antioxidants) and enhanced expression of the downstream antioxidant response element haeoxygenase-1 (HO-1) in the colon tissue. Also, the concentration of fecal hemoglobin and the myeloperoxidase specific oxidative damage biomarker 3-chlorotyrosine in the colon were significantly decreased in the presence of AZD3241. This latter result was consistent with AZD3241 inhibiting MPO activity in vitro. Overall, AZD3241 ameliorated the course and severity of experimental colitis through ameliorating MPO derived tissue damage and could be considered a potential therapeutic option, subject to further validation in chronic IBD models. |
format | Online Article Text |
id | pubmed-7522858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75228582020-10-09 The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis Ahmad, Gulfam Chami, Belal Liu, Yuyang Schroder, Angie L. San Gabriel, Patrick T. Gao, Antony Fong, Genevieve Wang, XiaoSuo Witting, Paul K. Front Pharmacol Pharmacology Chronic inflammatory bowel disease (IBD) is a condition with multifactorial pathophysiology. To date, there is no permanent cure and the disease is primarily managed by immunosuppressive drugs; long-term use promotes serious side effects including increased risk malignancies. The current study aimed to target neutrophil-myeloperoxidase, a key contributor to the pathogenesis of IBD, through the use of AZD3241that inhibits extracellular myeloperoxidase. Experimental colitis was induced in C57BL/6 male mice by 2% dextran sodium sulfate in drinking water ad libitum over 9 days. Mice received either normal drinking water and peanut butter (control), 2% DSS in drinking water and peanut butter or 2% DSS in drinking water and AZD3241 (30 mg/kg) dispersed in peanut butter daily for 9 days. Administered AZD3241 attenuated body weight loss (10% p<0.05) and improved clinical score (9 fold p<0.05; a score comprising the time-dependent assessment of stool consistency and extent of rectal bleeding), loss of colonic crypts (p<0.001), preserved surface epithelium (p<0.001) and enhanced expression of the transcription factor Nrf-2 (regulator of antioxidants) and enhanced expression of the downstream antioxidant response element haeoxygenase-1 (HO-1) in the colon tissue. Also, the concentration of fecal hemoglobin and the myeloperoxidase specific oxidative damage biomarker 3-chlorotyrosine in the colon were significantly decreased in the presence of AZD3241. This latter result was consistent with AZD3241 inhibiting MPO activity in vitro. Overall, AZD3241 ameliorated the course and severity of experimental colitis through ameliorating MPO derived tissue damage and could be considered a potential therapeutic option, subject to further validation in chronic IBD models. Frontiers Media S.A. 2020-09-15 /pmc/articles/PMC7522858/ /pubmed/33041796 http://dx.doi.org/10.3389/fphar.2020.556020 Text en Copyright © 2020 Ahmad, Chami, Liu, Schroder, San Gabriel, Gao, Fong, Wang and Witting http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ahmad, Gulfam Chami, Belal Liu, Yuyang Schroder, Angie L. San Gabriel, Patrick T. Gao, Antony Fong, Genevieve Wang, XiaoSuo Witting, Paul K. The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis |
title | The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis |
title_full | The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis |
title_fullStr | The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis |
title_full_unstemmed | The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis |
title_short | The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis |
title_sort | synthetic myeloperoxidase inhibitor azd3241 ameliorates dextran sodium sulfate stimulated experimental colitis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522858/ https://www.ncbi.nlm.nih.gov/pubmed/33041796 http://dx.doi.org/10.3389/fphar.2020.556020 |
work_keys_str_mv | AT ahmadgulfam thesyntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT chamibelal thesyntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT liuyuyang thesyntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT schroderangiel thesyntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT sangabrielpatrickt thesyntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT gaoantony thesyntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT fonggenevieve thesyntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT wangxiaosuo thesyntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT wittingpaulk thesyntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT ahmadgulfam syntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT chamibelal syntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT liuyuyang syntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT schroderangiel syntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT sangabrielpatrickt syntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT gaoantony syntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT fonggenevieve syntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT wangxiaosuo syntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis AT wittingpaulk syntheticmyeloperoxidaseinhibitorazd3241amelioratesdextransodiumsulfatestimulatedexperimentalcolitis |